18 – 55
Non / Ex-smoker only
BODY MASS INDEX (BMI)
A study to investigate the safety and tolerability of a new drug for the treatment of Pulmonary Arterial Hypertension (PAH) which will be given via an inhaler
This study consists of a Screening Visit (to confirm your eligibility to enter the study) 1 treatment period of 28 days in duration (from afternoon before dosing, until 24 hrs after your first dose on Day 27) End of study Follow Up visit (Day 31 to 37)
Females wishing to participate in this study must be of non child bearing potential
Study dates and availability may change at any time. There is no guarantee that these studies will still be available or that the dates will be the same when you contact our call centre. We do our best to ensure that the information published is up-to-date.
Information about the medication involved in the study is not provided on this Web site to respect the industry confidentiality. For more information about a specific study, please contact one of our call centre agents at 0800 691995.
Please note that during the in-house portion of the study you are expected to remain at our clinic throughout the entire duration of the stay. Although you are free to withdraw your participation at any time during the study, leaving the premises before the end of the intended stay, will result in the termination of your participation in the study.